GPR84 belongs to a subgroup of GPCRs that respond to medium-chain fatty acids, the metabolic fragments released when fats are broken down. Because these fragments accumulate in tissues under metabolic stress, GPR84 is thought to act as a metabolic sensor for the immune system, translating changing lipid levels into altered cellular behavior. Decades of pharmacological studies have linked the receptor to macrophages, neutrophils and other innate immune cells, where its activation has been associated with amplified production of inflammatory signaling molecules. That association made GPR84 an attractive drug target for companies pursuing anti-inflammatory therapies, and it also made the receptor a cautionary tale: several clinical candidates targeting it were halted, in some cases because the biology proved more complicated than early animal studies suggested.

The central problem has been that GPCRs are not simple on-off switches. They are dynamic molecular machines that sample a range of conformations, and different ligands can stabilize different subsets of those conformations. A ligand that locks the receptor into a fully active shape will recruit signaling proteins robustly, while a ligand that favors inactive shapes will silence the pathway. But many ligands do something subtler: they stabilize partially active conformations, or they favor active shapes in one signaling branch while leaving others untouched. Without structural information, medicinal chemists were essentially adjusting molecular shapes blindly, hoping that small changes in a ligand scaffold would produce predictable changes in receptor behavior.

The new study addresses that gap by capturing GPR84 in two distinct functional states, allowing the researchers to compare the receptor’s architecture when it is being activated against its architecture when it is being blocked or modulated. Structures determined in multiple states are technically demanding, because a membrane-embedded receptor must be stabilized in each conformation long enough to be imaged at atomic resolution. Achieving this typically requires engineered variants, stabilizing antibodies or nanobodies, and carefully chosen ligands that preferentially hold the receptor in the desired state. The resulting paired structures function like two frames of a molecular movie, revealing which helices shift, which side chains rotate, and which structural water molecules rearrange as the receptor transitions between resting and signaling-competent forms.

Comparing the two states highlights the allosteric heart of the receptor. In GPCRs, ligand binding at a pocket nestled among the transmembrane helices is transmitted through a conserved relay of hydrogen bonds, salt bridges and hydrophobic contacts to the intracellular face, where G proteins and other effectors dock. The dual-state GPR84 structures delineate how agonist binding contracts this relay into the canonical active arrangement, with an inward movement of the extracellular portion of a key transmembrane helix and a corresponding outward swing on the intracellular side that opens the effector-binding cavity. In the inactive or antagonist-bound state, that same helix relaxes outward, the intracellular cavity collapses, and the network of polar interactions reconfigures into a pattern incompatible with effector coupling. The residue-by-residue map of these changes gives chemists concrete positions to target when they want to bias the equilibrium toward one state or the other.

Crucially, the structural work is not left to stand alone. The authors couple it with functional assays performed in immune cells, measuring how well each ligand drives or suppresses downstream signaling and, importantly, how it affects inflammatory outputs such as cytokine release. This combination is what elevates the study from structural description to pharmacological instruction. A structure can suggest that a compound should be an agonist, but only cellular assays reveal the potency, the efficacy ceiling, and whether the compound behaves as a full agonist, a partial agonist or a biased ligand in a physiologically relevant context. By testing ligands across the spectrum, the researchers could correlate specific structural features of the binding pocket with specific functional consequences, effectively building a translation table between atomic geometry and immune cell behavior.

One of the more interesting implications concerns ligand bias, the phenomenon in which a receptor signals preferentially through one intracellular pathway over another. For GPR84, whose activation intersects with inflammatory programs in macrophages, a biased ligand could in principle dampen harmful signaling while preserving useful functions, or vice versa. The dual-state structures provide a mechanistic handle on bias: ligands that engage only part of the activation relay, or that fail to complete certain helical movements, may recruit one effector but not another. The immune functional assays then quantify what that partial engagement means for cytokine production, giving drug developers a rational framework for designing compounds with tailored signaling profiles rather than accepting whatever profile a scaffold happens to produce.

The study also speaks to the thorny issue of species differences, which has plagued GPR84 drug development. Synthetic agonists developed against the human receptor have often shown sharply different potency in mouse models, complicating the interpretation of preclinical efficacy studies and contributing to the sector’s clinical disappointments. Although the structures presented are of the human receptor, the detailed pocket architecture allows researchers to pinpoint which residues differ across species and to predict, before expensive animal work, whether a given compound is likely to translate. That kind of structural triage could save years of effort and redirect resources toward candidate molecules with a realistic chance of reproducing human biology in animal systems.

Beyond immediate drug design, the work contributes to a broader shift in GPCR pharmacology toward state-based thinking. Rather than classifying ligands simply as agonists, antagonists or inverse agonists, the field increasingly describes them by the conformational ensembles they stabilize and the signaling outputs those ensembles produce. GPR84, with its metabolic ligands, its immune cell expression and its checkered clinical history, is an ideal test case for this framework. The demonstration that paired structures plus immune assays can jointly explain and predict pharmacological behavior provides a template that other lipid-sensing and metabolite-sensing receptors could follow, particularly those where immune modulation is the therapeutic goal.

For patients, the significance lies in what this molecular clarity could eventually enable. Chronic inflammatory and metabolic diseases, including conditions involving macrophage-driven tissue damage, remain areas of substantial unmet need, and receptors that sense the metabolic environment of inflamed tissue are logical points of intervention. By showing exactly how ligands of different pharmacological classes occupy the GPR84 binding pocket and drive or block its conformational changes, the study turns a previously opaque target into an addressable one. The next steps, testing structure-guided ligand designs and validating their immune effects in disease models, will determine how quickly this structural knowledge moves from the pages of a journal toward the clinic, but the roadmap for modulating GPR84 rationally is now drawn.

Subject of Research: Structural and pharmacological modulation of the lipid-sensing immune receptor GPR84

Article Title: Pharmacological modulation of GPR84 revealed by dual states structures and immune functional assays

Article References: Choi, M. K., Park, D. J., Kim, P., Choi, H. S., Myung, S., Yoo, Y., Chang, N., Yoon, G.-Y., Kang, H. J., Ha, S.-J., & Cho, H.-S. (2026). Pharmacological modulation of GPR84 revealed by dual states structures and immune functional assays. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01841-w

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01841-w

Keywords: GPR84, G protein-coupled receptor, dual-state structures, immune functional assays, ligand bias, inflammatory signaling, macrophages, medium-chain fatty acids, structural biology, drug discovery, Pharmacological, modulation

Farnesol is an acyclic sesquiterpene alcohol found in essential oils of numerous plants, including lemongrass, chamomile, and balsam trees, and it has long been valued in the flavor and fragrance industries. In recent years, however, it has attracted serious scientific attention for its pharmacological properties, including anti-inflammatory and anticancer effects demonstrated in several malignancies ranging from prostate cancer to osteosarcoma and colorectal carcinoma. Earlier work had shown that farnesol can trigger apoptosis, or programmed cell death, in human lung carcinoma cells through the endoplasmic reticulum stress response, and that it can interfere with epithelial-to-mesenchymal transition via the Akt/mTOR pathway. What remained poorly understood was its specific mechanism of action against invasion and metastasis in NSCLC, the context in which the Alagappa University team, led by corresponding author Kasi Pandima Devi, conducted their investigation using A549 lung adenocarcinoma cells as a model system.

The experimental design combined two-dimensional and three-dimensional approaches, a strategy that reflects the growing recognition that conventional flat-cell cultures often fail to capture the complexity of tumors in the body. In the 2D phase of the study, the researchers first established the cytotoxic profile of farnesol, finding that it reduced A549 cell viability in a dose-dependent manner with an IC₅₀ value of 21.5 micrograms per milliliter. Under the microscope, treated cells displayed characteristic signs of distress: shrinkage and a loss of cell density, indicating that the compound was exerting a genuine cytotoxic effect rather than merely slowing proliferation. This concentration then served as the reference point for the subsequent functional assays probing cell motility and invasiveness.

To assess migration, the team performed scratch assays, a classic wound-healing test in which a confluent monolayer of cells is deliberately scratched and researchers measure how quickly cells crawl back into the gap. In parallel, they used Matrigel-assisted transwell invasion assays, which are considerably more demanding: cells must digest through a protein-rich extracellular matrix barrier before they can migrate through a porous membrane. Both assays told the same story. Farnesol-treated cultures showed marked inhibition of migration and invasion, with substantially increased nonmigratory spaces compared to untreated controls. In other words, the compound did not just kill the cells; it crippled their ability to execute the coordinated movements that metastasis requires, even at sublethal exposures.

The molecular underpinnings of this impairment were then dissected using immunofluorescence staining, western blotting, and real-time quantitative PCR. The results converged on a well-known villain in cancer biology: the epithelial-to-mesenchymal transition, or EMT. EMT is a developmental program that cancer cells hijack, allowing epithelial cells that normally adhere tightly to their neighbors to lose their identity, gain motile mesenchymal characteristics, and invade surrounding tissue. A central molecular event in EMT is the so-called cadherin switch, in which the epithelial adhesion molecule E-cadherin is lost and replaced by mesenchymal cadherins. Farnesol treatment reversed this switch in A549 cells, upregulating E-cadherin, the molecular “glue” that holds epithelial cells together, while simultaneously suppressing a battery of mesenchymal and matrix-remodeling markers.

Particularly significant was the compound’s effect on the hypoxia-associated signaling axis. Solid tumors often outgrow their blood supply, creating oxygen-poor regions that activate hypoxia-inducible factor 1 alpha (HIF1A), a master transcriptional regulator that reprograms cancer cells for survival, angiogenesis, and invasion. The study found that farnesol suppressed HIF1A along with COX2, the cyclooxygenase enzyme long implicated in tumor inflammation and metastatic potential, and PCAF, a histone acetyltransferase previously identified as part of an alliance promoting lung cancer malignancy. Downstream of these regulators, the researchers observed reduced expression of vascular endothelial growth factor (VEGF), the principal driver of tumor angiogenesis, and diminished activity of matrix metalloproteinases MMP2 and MMP9, the enzymatic scissors cancers use to degrade the extracellular matrix and clear a path for invasion. Immunofluorescence analysis further confirmed that farnesol blunted the angiogenic potential of A549 cells through VEGF suppression, suggesting the compound attacks metastasis at multiple, mutually reinforcing levels: adhesion, matrix degradation, and blood vessel recruitment.

The 3D phase of the study provided perhaps the most visually compelling evidence. Using hanging-drop spheroid cultures, which coax cancer cells into self-organizing into compact, tumor-like spheres, the researchers exposed these microtumors to farnesol and tracked their structural integrity. Three-dimensional spheroids are widely regarded as superior models for drug screening because they recreate key features of real tumors, including oxygen and nutrient gradients, cell-to-cell adhesion, and a hypoxic core. Farnesol treatment significantly reduced spheroid diameter and caused a visible dissociation of spheroid integrity, effectively loosening the cohesive architecture that tumors depend on. At concentrations above 125 micrograms per milliliter, the compound induced apoptosis within the spheroids, pushing the cells from impaired function to outright self-destruction. The transition from 2D mechanistic insight to 3D tumor-like validation strengthens the case that these are not artifacts of an oversimplified culture system.

The findings build coherently on the team’s own earlier work. In a prior study published in Medical Oncology, the same group demonstrated that farnesol induces apoptosis in A549 cells, modulates autophagy through LC3B and SQSTM1-mediated regulation, and downregulates anaerobic glycolysis via suppression of lactate dehydrogenase and PKM, targeting the metabolic reprogramming known as the Warburg effect. The new study extends this picture from metabolism and cell death into the realm of invasion and metastasis, mapping farnesol’s effects onto the EMT, hypoxia, and angiogenesis pathways. Together, the two papers sketch a compound that strikes lung cancer cells on several fronts simultaneously, a property that is especially valuable in oncology, where single-target agents are often defeated by compensatory signaling.

The clinical significance of targeting EMT and hypoxia signaling in lung cancer can hardly be overstated. EMT is intimately connected not only to invasion but also to therapeutic resistance, including resistance to chemotherapy and targeted agents, because mesenchymal cells tend to be more resilient against apoptosis-inducing treatments. HIF1A-driven hypoxic responses are similarly implicated in vasculogenic mimicry, a sinister process in which aggressive tumor cells form channel-like structures that supplement blood supply independent of normal angiogenesis. By suppressing HIF1A, COX2, and PCAF while restoring E-cadherin and curbing VEGF and MMP activity, farnesol appears to hit the metastatic program at its regulatory源头, upstream of the effector mechanisms. A compound capable of reversing this program could, in principle, sensitize tumors to existing therapies and reduce the risk of metastatic spread, the single most lethal feature of lung adenocarcinoma.

Nevertheless, the road from laboratory finding to clinical application is long and demands caution. All results reported in this study are in vitro, derived from a single cell line and its 3D spheroid derivatives. Whether farnesol can achieve comparable concentrations in human tumors after oral or systemic administration, whether it will show acceptable toxicity toward healthy lung and other tissues, and whether the effects will hold in animal models and ultimately in patients remain open questions. The field of natural product oncology is littered with compounds that dazzled in culture dishes but faltered later, which is why the researchers emphasize farnesol as a “therapeutic candidate” and a lead for further development rather than a ready-made treatment. Encapsulation strategies, such as the chitosan-based delivery systems previously explored with related terpenes, may ultimately be needed to improve bioavailability and potency.

Still, the study adds a valuable entry to the growing catalog of natural products with activity against lung cancer, a category that has gained momentum as researchers search the tumor microenvironment for new points of intervention. The work was supported by funding from the CMRG program, RUSA 2.0, and an ICMR Ad hoc project, reflecting a concerted national investment in exploring India’s rich pharmacological heritage. If subsequent preclinical studies confirm that farnesol or optimized derivatives can suppress EMT and hypoxia signaling in living tumors, this fragrant plant molecule, better known for its role in perfumes and flavorings, may one day find an unexpected second career in the fight against the world’s deadliest cancer.